| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| 영문 | connective tissue | 한글 | 결합조직 |
|---|---|---|---|
| 설명 | 체내에 널리 분포하며, 장기, 조직사이를 메우고 그것을 기계적으로 지지, 조직이다. 그밖에 혈관, 림프관, 신경을 인도하며 영양, 대사산물의 수송 또는 저류, 나아가서는 손상, 감염에 대한 방어 또는 수복 등에도 작용한다. 결합조직은 세포간질이 풍부하며, 세포간질을 구성하는 기질과 섬유의 성상에 따라 간엽조직, 섬유성 결합조직(성긴섬유성 결합조직, 촘촘한 섬유성 결합조직), 지방조직, 탄성조직, 세망 조직 등으로 분류된다. |
||
| 영문 | osseous tissue | 한글 | 뼈조직, 골조직 |
|---|---|---|---|
| 설명 | 골세포와 골세포주위의 딱딱한 칼슘조직으로 둘러싸인 밀집된 결합조직을 뜻한다. 이 골조직에 의해서 뼈가 이루어져 인체의 골격을 형성한다. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| TF | free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ... |
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| PAF | paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl... |
| LDL-C | lipoprotein cholesterol and low-density lipoprotein cholesterol |
|---|---|
| ATLPL | Adipose tissue lipoprotein lipase |
| CTGF | Connective Tissue Growth Factor |
| TF | FVIIa/tissue factor |
| rTFPI | Recombinant tissue factor pathway inhibitor |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
acute angle
| platelet tissue factor | <haematology> Traditional name for substance in plasma that converts prothrombin to thrombin. Now known not to be a single substance. (See thrombin). (18 Nov 1997) |
|---|---|
| tissue factor | <cell biology> Integral membrane glycoprotein of around 250 residues, that initiates blood clotting after binding factors VII or VIIa. (18 Nov 1997) |
| tissue weighting factor | In radiation protection, a factor weighting the equivalent dose in a particular tissue or organ in terms of its relative contribution to the total deleterious effects resulting from uniform irradiation of the whole body. See: effective dose. (05 Mar 2000) |
| a1-lipoprotein | A lipoprotein fraction of relatively low molecular weight, high density, rich in phospholipids, and found in the a1-globulin fraction of human plasma. (05 Mar 2000) |
| b1-lipoprotein | A lipoprotein fraction of relatively high molecular weight, low density, rich in cholesterol, and found in the beta-globulin fraction of human plasma. (05 Mar 2000) |
| receptors, lipoprotein | Cell surface proteins that bind lipoproteins with high affinity. Lipoprotein receptors in the liver and peripheral tissues mediate the regulation of plasma and cellular cholesterol metabolism and concentration. The receptors generally recognise the apolipoproteins of the lipoprotein complex, and binding is often a trigger for endocytosis. (12 Dec 1998) |
| very low density lipoprotein | <biochemistry> A lipoprotein substances (combination of a fat and a protein) which acts as a carrier for cholesterol and fats (particularly triglycerides) in the bloodstream. Elevations in very low density lipoprotein in the bloodstream are associated with an increased risk of atherosclerosis and coronary artery disease. Acronym: VLDL (18 Nov 1997) |
| multiple lipoprotein-type hyperlipidaemia | <biochemistry> Inherited as a defective gene, this disorder is characterised by elevations in serum cholesterol and/or triglycerides. There are often multiple types of lipoproteins (LDL) elevated in one family. This condition is associated with an increased risk of cardiovascular disease. Origin: Gr. Haima = blood (27 Sep 1997) |
| high density lipoprotein | <biochemistry> These lipoproteins acts to carry cholesterol in the bloodstream. Raised high density lipoprotein levels have been correlated with a lower risk for heart disease. Less than 35 mg/dl is considered a positive risk factor for coronary artery disease, over 60 mg/dl is considered a negative risk factor (reduces your risk of heart disease). Recent studies show a low high density lipoprotein level is the strongest predictor of cardiovascular death in women. Acronym: HDL (18 Nov 1997) |
| intermediate density lipoprotein | Class of lipoproteins formed in degradation of very-low-density lipoproteins; about half are cleared quickly from the plasma into the liver by receptor-mediated endocytosis; the other half are degraded into low density lipoproteins. (05 Mar 2000) |
| familial high density lipoprotein deficiency | Familial high {density lipoprotein deficiency}; a heritable disorder of lipid metabolism characterised by almost complete absence from plasma of high density lipoproteins, and by storage of cholesterol esters in foam cells, tonsillar enlargement, an orange or yellow-gray colour of the pharyngeal and rectal mucosa, hepatosplenomegaly, lymph node enlargement, corneal opacity, and peripheral neuropathy; autosomal recessive inheritance. Synonym: familial high {density lipoprotein deficiency}, Tangier disease. Origin: G. An-, priv., + alpha, a, + lipoprotein + -aemia, blood (05 Mar 2000) |
| familial lipoprotein lipase deficiency | An rare inherited disorder where there is a deficiency of an enzyme (lipoprotein lipase) which breaks down fat molecules, causing the accumulation of fats or lipoproteins in the blood. Symptoms in infancy include abdominal pain (appears as if its colic), failure to thrive and skin lesions (xanthomas). (27 Sep 1997) |
| familial lipoprotein lipase inhibitor | An inhibitor found in certain individuals that inhibits lipoprotein lipase resulting in accumulation of chylomicrons, VLDL, and triacylglycerols; similar in symptoms to familial lipoprotein lipase deficiency. (05 Mar 2000) |
| lipoprotein | <biochemistry> An important class of serum proteins in which a spherical hydrophobic core of triglycerides or cholesterol esters surrounded by an amphipathic monolayer of phospholipids, cholesterol and apolipoproteins. Classified according to density: chylomicrons, large low density particles, very low density, low density and high density species. Important in lipid transport, especially cholesterol transport in the blood stream. Abnormalities in lipoprotein metabolism have been implicated in certain heart diseases. (13 Nov 1997) |
| lipoprotein(a) | A family of lipoprotein particles varying in density and size depending on the protein-lipid ratio and the protein composition. These particles consist of apolipoprotein b-100 covalently linked to apolipoprotein-a by one or two disulfide bonds. There is a correlation between high plasma levels of this lipoprotein and increased risk for atherosclerotic cardiovascular disease. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|